# US 2026/0083707 A1 · Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083707 A1
- Document ID: US20260083707A1
- Status: Published application
- Kind: A1
- Application number: 19/282,336
- Filed: 2025-07-28
- Published: 2026-03-26
- Earliest claimed: 2017-06-13
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Thomas Jorg Mehrling; Marco Herling
- Web page: https://patentgrep.com/patent/US20260083707A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.

## Claims

### Claim at position 1

-11. (canceled)

### Claim 12

A method of treating T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof, comprising parenterally administering to said patient tinostamustine or a pharmaceutically acceptable salt thereof at a dosage level of from 20 mg/m2 to 150 mg/m2 body surface area of the patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the T-PLL is relapsed, refractory T-PLL, or a combination thereof.

### Claim 14 (depends on 12)

The method of claim 12, wherein the T-PLL is metastatic.

### Claim 15 (depends on 12)

The method of claim 12, wherein the T-PLL is advanced.

### Claim 16 (depends on 12)

The method of claim 12, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof.

### Claim 17 (depends on 12)

The method of claim 12, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intramuscularly to the patient in need thereof.

### Claim 18 (depends on 12)

The method of claim 12, wherein the tinostamustine or pharmaceutically acceptable salt thereof is contained in a composition, and wherein the composition comprises a liquid carrier selected from the group of polyethylene glycol, cyclodextrin, and a fatty oil.

### Claim 19 (depends on 18)

The method of claim 18, wherein the liquid carrier is cyclodextrin.

### Claim 20 (depends on 12)

The method of claim 12, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered to the patient on Day 1 of a 21 day treatment cycle.

### Claim 21 (depends on 12)

The method of claim 12, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered to the patient in need thereof over an administration time of 45 minutes.

### Claim 22 (depends on 12)

The method of claim 12, wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered to the patient in need thereof over an administration time of 60 minutes.
